Market Closed -
OTC Markets
03:42:02 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.0044
USD
|
0.00%
|
|
-2.22%
|
-78.00%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
214.5
|
204.1
|
192.7
|
346
|
212.3
|
14.16
|
Enterprise Value (EV)
1 |
185.2
|
153.1
|
158.3
|
295.1
|
184.7
|
13.81
|
P/E ratio
|
-6.24
x
|
-8
x
|
-4.19
x
|
-4.17
x
|
-2.31
x
|
-0.14
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
57.9
x
|
8.4
x
|
34.2
x
|
240
x
|
38.5
x
|
2.66
x
|
EV / Revenue
|
50
x
|
6.3
x
|
28.1
x
|
205
x
|
33.5
x
|
2.59
x
|
EV / EBITDA
|
-5.68
x
|
-6.17
x
|
-3.54
x
|
-3.81
x
|
-2.16
x
|
-0.21
x
|
EV / FCF
|
-12.8
x
|
-12.4
x
|
-7.23
x
|
-8.92
x
|
-4.09
x
|
-0.64
x
|
FCF Yield
|
-7.83%
|
-8.09%
|
-13.8%
|
-11.2%
|
-24.5%
|
-157%
|
Price to Book
|
9.45
x
|
4.82
x
|
8.45
x
|
11.3
x
|
13.4
x
|
-0.63
x
|
Nbr of stocks (in thousands)
|
4,741
|
5,670
|
6,267
|
7,908
|
9,409
|
16,861
|
Reference price
2 |
45.25
|
36.00
|
30.75
|
43.75
|
22.56
|
0.8400
|
Announcement Date
|
3/15/18
|
3/15/19
|
3/16/20
|
3/25/21
|
3/15/22
|
4/3/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
3.708
|
24.29
|
5.633
|
1.44
|
5.514
|
5.325
|
EBITDA
1 |
-32.6
|
-24.81
|
-44.79
|
-77.44
|
-85.63
|
-65.55
|
EBIT
1 |
-33.28
|
-25.66
|
-45.49
|
-78.33
|
-86.56
|
-66.97
|
Operating Margin
|
-897.6%
|
-105.64%
|
-807.53%
|
-5,439.72%
|
-1,569.79%
|
-1,257.63%
|
Earnings before Tax (EBT)
1 |
-32.24
|
-24.28
|
-44.58
|
-78.76
|
-86.96
|
-72.53
|
Net income
1 |
-32.24
|
-24.28
|
-44.58
|
-78.76
|
-86.96
|
-72.53
|
Net margin
|
-869.5%
|
-99.97%
|
-791.44%
|
-5,469.79%
|
-1,576.99%
|
-1,362.14%
|
EPS
2 |
-7.250
|
-4.500
|
-7.347
|
-10.50
|
-9.750
|
-6.072
|
Free Cash Flow
1 |
-14.5
|
-12.38
|
-21.91
|
-33.1
|
-45.2
|
-21.66
|
FCF margin
|
-390.99%
|
-50.97%
|
-389.01%
|
-2,298.58%
|
-819.82%
|
-406.73%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/15/18
|
3/15/19
|
3/16/20
|
3/25/21
|
3/15/22
|
4/3/23
|
Fiscal Period: December |
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
-
|
4.792
|
0.722
|
2.912
|
-
|
-
|
0.032
|
-
|
0.049
|
-
|
EBITDA
|
-21.85
|
-16
|
-
|
-22.13
|
-23.64
|
-16.1
|
-
|
-
|
-
|
-
|
EBIT
1 |
-22.57
|
-16.22
|
-21.68
|
-22.38
|
-24.26
|
-16.71
|
-13.66
|
-
|
-12.99
|
-7.78
|
Operating Margin
|
-
|
-338.52%
|
-3,002.08%
|
-768.48%
|
-
|
-
|
-42,687.5%
|
-
|
-26,506.12%
|
-
|
Earnings before Tax (EBT)
|
-22.6
|
-16.18
|
-21.71
|
-22.22
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-22.6
|
-16.18
|
-21.71
|
-22.22
|
-23.65
|
-13.67
|
-13
|
-
|
-12.92
|
-3.771
|
Net margin
|
-
|
-337.58%
|
-3,007.06%
|
-762.91%
|
-
|
-
|
-40,628.12%
|
-
|
-26,375.51%
|
-
|
EPS
2 |
-2.500
|
-1.750
|
-2.250
|
-2.250
|
-2.250
|
-1.150
|
-0.8300
|
-0.4300
|
-0.6200
|
-0.1500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/9/21
|
11/15/21
|
3/15/22
|
5/6/22
|
8/11/22
|
11/14/22
|
3/31/23
|
5/15/23
|
8/16/23
|
11/16/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
29.3
|
51.1
|
34.4
|
50.9
|
27.6
|
0.35
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-14.5
|
-12.4
|
-21.9
|
-33.1
|
-45.2
|
-21.7
|
ROE (net income / shareholders' equity)
|
-187%
|
-73%
|
-134%
|
-288%
|
-364%
|
1,939%
|
ROA (Net income/ Total Assets)
|
-79%
|
-33.7%
|
-55%
|
-96.6%
|
-90.2%
|
-95.2%
|
Assets
1 |
40.8
|
72.16
|
81.07
|
81.55
|
96.36
|
76.18
|
Book Value Per Share
2 |
4.790
|
7.470
|
3.640
|
3.880
|
1.690
|
-1.330
|
Cash Flow per Share
2 |
6.000
|
8.850
|
5.480
|
6.380
|
3.850
|
0.5000
|
Capex
1 |
0.29
|
1.53
|
0.58
|
1.16
|
1.36
|
0.4
|
Capex / Sales
|
7.69%
|
6.31%
|
10.28%
|
80.69%
|
24.66%
|
7.46%
|
Announcement Date
|
3/15/18
|
3/15/19
|
3/16/20
|
3/25/21
|
3/15/22
|
4/3/23
|
|
1st Jan change
|
Capi.
|
---|
| -78.00% | 272K | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|